TRVN250321C7500
- 0.00
- 0.000.00%
Trevena Newsroom
JMP Securities Downgrades Trevena(TRVN.US) to Hold Rating
Trevena Cut to Neutral From Buy by HC Wainwright & Co.
Trevena Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Trevena Analyst Ratings
H.C. Wainwright Downgrades Trevena(TRVN.US) to Hold Rating, Cuts Target Price to $5
Analysis of Trevena's Hold Rating: Balancing High Potential Assets With Financial Instability
Buy Rating Affirmed for Trevena Amid Strong TRV-045 Development Progress and Stable Financial Position
HC Wainwright & Co. : Maintaining the Trevena (TRVN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $5.00.
Trevena Analyst Ratings
HC Wainwright & Co. Maintains Buy on Trevena, Lowers Price Target to $5
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising Drug TRV045
Analysts Are Bullish on These Healthcare Stocks: Pliant Therapeutics (PLRX), Trevena (TRVN)
Trevena Analyst Ratings
HC Wainwright & Co. Maintains Buy on Trevena, Maintains $9 Price Target
Buy Rating Affirmed on Trevena as Focus Shifts to Promising Drug Candidate TRV045
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising TRV045 Development
Trevena Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Trevena, Maintains $9 Price Target
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN), MoonLake Immunotherapeutics (MLTX) and Senseonics Holdings (SENS)
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN) and Immunic (IMUX)